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Abstract
Background: The advent of prostate specific antigen (PSA) testing in the United States of America
(USA) has led to a dramatic increase in the incidence of prostate cancer in the United States as well
as the number of men undergoing aggressive treatment with radical prostatectomy and radiation
therapy. We compared patient characteristics and treatment selection between American men
with screening-detected versus clinically diagnosed prostate cancers.
Methods: We evaluated 3,173 men with prostate cancer in the USA. Surveys and medical records
provided information on demographics, socioeconomic status, comorbidities, symptoms, tumor
characteristics, and treatment. We classified men presenting with symptoms of advanced cancer –
bone pain, weight loss, or hematuria – as "clinically diagnosed"; asymptomatic men and those with
only lower urinary tract symptoms were considered "screening-detected." We used multivariate
analyses to determine whether screening predicted receiving aggressive treatment for a clinically
localized cancer.
Results: We classified 11% of cancers as being clinically diagnosed. Men with screening-detected
cancers were more often non-Hispanic white (77% vs. 65%, P < 0.01), younger (36% < 65 years vs.
25%, P ≤  0.01), better educated (80% ≥  high school vs. 67%, P < 0.01), healthier (18% excellent
health vs. 10%, P < 0.01), and diagnosed with localized disease (90% vs. 75%, P < 0.01). Men with
screening-detected localized cancers more often underwent aggressive treatment, 76% vs. 70%, P
= 0.05.
Conclusion: Most cancers were detected by screening in this American cohort. Appropriately,
younger, healthier men were more likely to be diagnosed by screening. Minority status and lower
socio-economic status appeared to be screening barriers. Screening detected earlier-stage cancers
and was associated with receiving aggressive treatment.
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Background
Prostate-specific antigen (PSA) testing was introduced in
the United States of America (USA) in the late 1980s with
Federal Drug Administration (FDA) approval for prostate
cancer surveillance [1]. However, the test indications were
soon expanded to include prostate cancer screening. By
the early 1990s, the American Urologic Association and
the American Cancer Society were recommending PSA
testing, along with digital rectal examination (DRE), as
part of annual prostate cancer screening [2,3]. The advent
of PSA testing led to a dramatic increase in the incidence
of prostate cancer in the USA, with the number of new
cases rising from 152,811 in 1990 to over 230,000 in
1992 [4,5]. During the past decade, the number of Amer-
ican men undergoing aggressive treatment with radical
prostatectomy and radiation therapy also increased sub-
stantially [6,7].
Urologic screening studies provide the most comprehen-
sive information about the men undergoing PSA screen-
ing [8-10]. Several trials have taken place in both Europe
and the USA. In general, study subjects usually were
recruited through advertisements and they were screened
with combinations of PSA, DRE, and transrectal ultra-
sound. The average age of these study participants was in
the mid-60s, and minority subjects were not well repre-
sented. Minimal data were provided on symptoms,
comorbidity, or socioeconomic status. Among American
men diagnosed with clinically localized prostate cancers,
approximately 90% underwent treatment with radical
prostatectomy or radiation therapy.
Population-based data on PSA screening are largely una-
vailable, including information on the proportion of
prostate cancers diagnosed by screening, the demo-
graphic, socioeconomic, and clinical characteristics of
men with screening-detected cancers, and the association
of screening detection with treatment decisions. We used
data from the United States-based Prostate Cancer Out-
comes Study (PCOS) to 1) determine the proportion of
screening-detected prostate cancers in a population-based
cohort, 2) compare baseline demographic, socioeco-
nomic, and clinical characteristics between men with
screening-detected versus clinically diagnosed cancers,
and 3) determine whether men with screening-detected
clinically-localized prostate cancers were more likely to
undergo aggressive treatment (radical prostatectomy or
radiation therapy).
Methods
Study population
The American National Cancer Institute instituted the
PCOS in 1994 to measure practice patterns and health-
related quality of life among men diagnosed with prostate
cancer in the United States. Methods for this multi-site,
longitudinal project are described elsewhere [11]. Briefly,
PCOS subjects were men histologically diagnosed with
prostate cancer between October 1, 1994 and October 31,
1995. Subjects were identified using a rapid case ascertain-
ment system by the six participating National Cancer
Institute Surveillance, Epidemiology and End Results
(SEER) cancer registries (Atlanta, Georgia metropolitan
area; Los Angeles County California; King County, Wash-
ington; Connecticut; Utah; and New Mexico). Eligible
subjects were residents of the areas covered by these regis-
tries at the time of diagnosis and were between the ages of
39 and 89 years, except in King County, where only men
over 60 years were eligible. The institutional review board
of each participating institution approved the study.
Eligible patients were sampled within strata of age, race/
ethnicity, and tumor registry to approximate a sample rep-
resentative of the United States population of prostate
cancer patients. The PCOS oversampled younger men and
minorities and excluded patients with race/ethnicity other
than non-Hispanic white, African American, or Hispanic,
because their sample sizes were small.
A total of 11,137 men with prostate cancer comprised the
eligible patient population for the study and the PCOS
randomly selected 5,672 of these men. Among these
selected patients, 3173 (55.9%) completed a health-
related quality-of-life survey questionnaire 6 months after
initial diagnosis. We used survey and medical record data
collected from these subjects to evaluate differences in
patient characteristics and treatments between men with
screening-detected cancers and those who were diagnosed
clinically. Responders to the PCOS survey were younger
than non-responders and more likely to be non-Hispanic
white and have a higher socioeconomic status. A substan-
tial proportion of the responders had regional stage and
moderately differentiated cancers, while non-responders
had a greater proportion of distant stage and poorly differ-
entiated cancers. Responders also were more likely to
receive radical prostatectomy [11].
Data collection
Investigators contacted eligible subjects by mail and/or
telephone requesting them to sign a release form allowing
review of all medical records from any physicians and
facilities diagnosing and/or providing care for prostate
cancer. Records were obtained from private and public
hospitals, freestanding radiological or surgical centers,
Veterans Administration hospitals, Health Maintenance
Organizations, and private physician offices. Certified
Tumor Registry abstractors collected baseline information
on demographics, clinical symptoms before diagnosis
(systemic and urinary), comorbidity, diagnostic proce-
dures and results (including PSA levels and digital rectal
examination findings), clinical staging, tumorBMC Cancer 2005, 5:27 http://www.biomedcentral.com/1471-2407/5/27
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characteristics, and treatment details. The PCOS re-
abstracted a random sample of 5% of records to assess and
correct any systematic coding errors.
The PCOS also collected data on general and disease-spe-
cific measures of health-related quality of life, symptoms,
comorbidity, and specific treatments received for prostate
cancer using a mailed self-administered questionnaire.
Most respondents completed the self-administered ques-
tionnaire (91%); those who did not return the question-
naire were contacted by telephone and asked to complete
the survey by telephone or in person. Subjects were asked
to recall their health-related quality of life and symptoms,
including the domains of urinary, bowel, and sexual func-
tion, just before their prostate cancer was diagnosed.
Demographic and socioeconomic questions from this sur-
vey were used to determine race/ethnicity, employment
status, educational level, household income, insurance
status, and marital status. A question assessing comorbid-
ity asked about 12 medical conditions that were likely to
affect prostate cancer treatment decisions and long-term
quality of life. The conditions were derived from the
Charlson index as well as the expert opinion of the PCOS
investigators [12]. If the patient reported being told by a
doctor that he had cerebrovascular disease, inflammatory
bowel disease, liver disease, or ulcers, he received one
point on his comorbidity score for each condition. If the
patient reported that any of eight conditions – arthritis,
diabetes, depression, hypertension, chest pain, heart
attack, heart failure, or chronic lung disease – limited his
activity or required prescription medications, he received
1 additional point for each of these conditions. In the
analyses, comorbidity scores were divided into the catego-
ries of 0, 1, 2, and greater than or equal to 3 points.
We assigned screening status using information from the
medical record abstract and the patient questionnaire. We
considered men presenting with symptoms consistent
with advanced prostate cancer, including bone pain,
weight loss or hematuria, to be "clinically diagnosed." We
initially created separate categories for men with only irri-
tative or obstructive symptoms consistent with benign
prostatic hyperplasia and an asymptomatic group who
had neither prostate cancer nor lower urinary tract
symptoms.
Clinical cancer stage was based on an algorithm using
information abstracted from medical records. The algo-
rithm was necessary because the community-based medi-
cal records were not detailed enough to classify cases by
TNM (tumor, node, metastases) staging [13]. The algo-
rithm defined T1 tumors as confined to the prostate with
a normal digital rectal examination and no positive scans
(magnetic resonance imaging, computed tomography,
bone scan) or evidence of metastases. T2 tumors were
defined as confined to the prostate, with abnormal or sus-
picious digital rectal examinations, but no positive scans
or evidence of metastases. We defined clinically localized
cancers as either T1 or T2 tumors. Initial treatment, based
on medical record abstractions, was defined as treatment
received within the first six months after diagnosis. We
defined aggressive treatment as either radical prostatec-
tomy or radiation therapy. We defined conservative man-
agement as androgen deprivation, either surgical or
chemical, or watchful waiting.
Statistical analyses
Descriptive statistics were calculated for ethnicity/race,
age, stage at diagnosis, education, marital status, employ-
ment, income, digital rectal exam and PSA results,
Gleason score from biopsy or transurethral resection of
the prostate, comorbid conditions and self-reported gen-
eral health status. We used contingency tables to compare
men presenting without any symptoms, those with lower
urinary tract symptoms alone, and those with prostate
cancer symptoms. Although screening is defined as apply-
ing a diagnostic test to asymptomatic people [14], the
prevalence of benign prostatic hyperplasia is very high
among men at risk for prostate cancer [15]. We found that
the men with only lower urinary tract symptoms were
much more similar to asymptomatic men than to men we
classified as having clinically diagnosed cancers. There-
fore, we also considered cancers diagnosed in men who
reported only lower urinary tract symptoms at the time of
PSA testing to be "screening-detected." We used this com-
bined screening-detected group to compare baseline char-
acteristics against clinically diagnosed cases and in
modeling treatment selection for clinically localized can-
cers. Logistic regression analyses were used to determine
whether screening history was independently associated
with selecting aggressive treatment versus conservative
management among men with clinically localized pros-
tate cancer. Covariates for this multivariate model, based
on previous literature, included age, race/ethnicity, mari-
tal status, study site, education, insurance status, annual
income, comorbidity, health status, and tumor character-
istics [16,17]. We also examined interactions between
screening status with age, comorbidity, PSA level, and
Gleason score.
The results of the logistic regression models are shown as
percentages receiving the treatment of interest, adjusting
for the independent variables included in the model.
These percentages were directly adjusted to the distribu-
tion of the variables among the weighted sample used in
each model [18]. The probability of receiving the treat-
ment of interest can then be directly compared across lev-
els of the variables included in the model.BMC Cancer 2005, 5:27 http://www.biomedcentral.com/1471-2407/5/27
Page 4 of 9
(page number not for citation purposes)
All analyses were performed with the Survey Data Analysis
statistical package (Research Trial Institute, Research Tri-
angle Park, North Carolina, 1997) to account for the com-
plex survey design. We obtained unbiased estimates of
parameters for all eligible prostate cancer patients in the
PCOS areas by using the Horvitz-Thompson weight,
which is the inverse of the sampling proportion for each
sampling stratum (defined by age, race/ethnicity, and
study area). A two-tailed P-value of < .05 was considered
statistically significant.
Results
The baseline demographic, socioeconomic, and clinical
characteristics of the PCOS subjects are shown in Tables 1
and 2. The majority of subjects were non-Hispanic white
men, older than sixty-five, and married at the time of diag-
nosis. Socioeconomic status was relatively high; a major-
ity had more than a high school education, and a
substantial proportion of subjects had private insurance.
Among the study subjects, 10.7% presented with symp-
toms consistent with prostate cancer and were considered
to be clinically diagnosed cases. Nearly two-thirds of sub-
jects had lower urinary tract symptoms, while 30.9% were
completely asymptomatic. Overall, 83.1% of men rated
their general health at "good" or "excellent" before their
cancer diagnosis.
We compared baseline characteristics of asymptomatic
men, those with lower urinary tract symptoms alone, and
men with clinically diagnosed cancers in Table 3. We
found that the characteristics of men with lower urinary
tract symptoms alone were closer to the asymptomatic
men than to the clinically diagnosed cancer cases for race/
ethnicity, socioeconomic status, health status, and cancer
Table 1: Baseline demographic and socioeconomic 
characteristics.
Variable Number of 
subjects (Sample 
size = 3173)
Weighted 
percentages
SEER registry
Atlanta 316 22.5
Connecticut 669 35.8
Los Angeles 938 13.5
New Mexico 342 11.5
Seattle 325 6.0
Utah 583 10.8
Ethnicity
Non-Hispanic white 2187 75.7
Non-Hispanic black 539 13.8
Hispanic 447 10.5
Age
< 49 102 2.3
50–64 1137 32.3
65–74 1336 44.5
75+ 598 20.9
Current marital status
Married 2499 78.6
Unmarried 637 20.3
Unknown 37 1.1
Education
< High school degree 695 20.9
High school/some college 1419 43.6
≥  College degree 1014 34.0
Unknown 45 1.5
Insurance
Private 2595 82.1
Public/Medicare 309 10.0
Unknown 269 7.9
Income (annual)
< $20,000 792 23.3
$20 – 40,000 921 28.8
$40,000 + 1128 36.3
Unknown 332 11.6
Legend: SEER = Surveillance, Epidemiology, and End Results
Table 2: Baseline clinical characteristics.
Variable Number of 
subjects (sample 
size = 3173)
Weighted 
percentages
Symptoms
Asymptomatic 1001 30.9
Lower urinary alone 1832 58.4
Systemic 340 10.7
Comorbid conditions
None 1211 37.2
1 1008 32.5
25 2 0 1 6 . 3
3+ 434 13.9
Health status
Excellent 534 16.9
Good 2104 66.2
Fair or poor 500 15.9
Unknown 35 1.0
PSA (ng/ml)
<4 294 8.8
≥  4 2675 84.5
Unknown 204 6.7
Digital rectal examination
Abnormal 1741 54.8
Normal 1033 33.2
Unknown 399 12.0
Gleason score
2 – 4 481 13.9
5 – 7 2029 65.1
8 – 10 373 11.6
Unknown 290 9.4
Tumor stage
Local 2796 88.7
Regional 126 3.7
Advanced 251 7.6
Legend: PSA = prostate-specific antigenBMC Cancer 2005, 5:27 http://www.biomedcentral.com/1471-2407/5/27
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Table 3: Distribution of baseline demographic, socioeconomic, and clinical characteristics by screening status.
Variable Clinically diagnosed 
(weighted %)
Asymptomatic* (weighted 
%)
LUTS** (weighted %) Asymptomatic or LUTS*** 
(weighted %)
SEER registry P = 0.16* P = 0.31** P = 0.24***
Atlanta 14.2 14.2 12.9 13.3
Connecticut 19.1 24.7 21.9 22.9
Los Angeles 38.1 34.5 36.0 35.5
New Mexico 13.7 9.8 12.0 11.3
Seattle 4.3 5.9 6.4 6.2
Utah 10.5 10.9 10.8 6.8
Ethnicity P < 0.01 P < 0.01 P < 0.01
Non-Hispanic white 65.1 79.9 75.5 77.0
Non-Hispanic black 20.8 12.4 13.3 13.0
Hispanic 14.1 7.8 11.2 10.0
Age P < 0.01 P = 0.38 P ≤  0.01
< 49 2.2 4.1 1.4 2.3
50–64 22.8 40.5 29.7 33.4
65–74 50.7 38.7 46.5 43.8
75+ 24.4 16.7 22.4 20.5
Current marital status P < 0.01 P = 0.03 P = 0.01
Married 72.9 81.4 79.7 80.3
Unmarried 27.1 18.6 20.3 19.7
Education P < 0.01 P < 0.01 P < 0.01
< High school degree 33.3 16.2 21.7 19.8
High school/college 37.6 45.5 44.8 45.0
≥  College degree 29.7 38.3 33.5 35.2
Income (annual) P < 0.01 P = 0.01 P < 0.01
< $20,000 36.8 19.0 28.4 25.1
$20 – 40,000 35.9 30.3 33.2 32.2
$40,000 + 27.3 50.7 38.4 42.7
Insurance P < 0.01 P = 0.23 P = 0.01
Private 39.7 48.9 44.0 44.3
Public/Medicare 53.1 42.7 48.2 48.2
Unknown 6.4 8.4 7.9 8.1
Comorbid conditions P ≤  0.01 P = 0.41 P = 0.05
None 32.2 41.8 35.8 37.8
1 30.3 34.0 32.2 32.8
2 17.6 16.4 16.1 16.2
3+ 19.8 7.8 16.0 13.2
Health status P < 0.01 P < 0.01 P < 0.01
Excellent 9.9 23.0 15.2 17.9
Good 63.5 68.9 66.5 67.3
Fair or poor 26.6 8.1 18.3 14.8
PSA (ng/ml) P = 0.01 P = 0.20 P = 0.05
<4 11.7 7.0 9.3 8.5
≥  4 78.5 87.9 83.7 85.2
Unknown 9.8 5.1 7.0 6.4
Digital rectal examination P = 0.10 P = 0.07 P = 0.06
Abnormal 59.4 54.0 54.3 54.2
Normal 27.0 34.0 33.9 33.9
Unknown 13.6 12.0 11.7 11.9
Gleason score P < 0.01 P < 0.01 P < 0.01BMC Cancer 2005, 5:27 http://www.biomedcentral.com/1471-2407/5/27
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grade and stage. When we combined these two groups
into a single category of screening-detected cases, we
found significant differences between the screening-
detected and clinically diagnosed cases. Men with screen-
ing-detected cancers were more likely to be non-Hispanic
white, were younger age, and had a higher socioeconomic
status. They also reported being healthier and were more
likely to have early stage disease.
We then evaluated whether screening status independ-
ently predicted receiving aggressive treatment among the
2796 men who were diagnosed with clinically localized
cancer. The primary treatment for these men was radical
prostatectomy for 1535 (53.4%), while 518 (20.6%)
underwent radiation therapy, 671 (26.0%) were treated
conservatively; we had no treatment information for 72
subjects (2.5%). The results of the multivariate analysis
are shown in Table 4. After adjusting for age, race/ethnic-
ity, marital status, area of the country, education, insur-
ance coverage, annual income, comorbidity, self-reported
health status, and tumor characteristics, we found that
men with screening-detected cancers were more likely to
receive aggressive treatment. The adjusted percentage of
men with screening-detected cancers undergoing aggres-
sive treatment was 76% (95% CI 0.74, 0.78) vs. 70%
(95% CI 0.64, 0.76), in men with clinically diagnosed
cancers, OR = 1.5 (95% CI 1.1, 2.3), P = 0.05. Other fac-
tors that were significantly associated with aggressive
treatment included geographic area, ethnicity, age, marital
status, comorbidity, health status, and tumor characteris-
tics. We found no significant interactions for treatment
selection between screening status with age, comorbidity,
PSA level, or Gleason score.
Discussion
We found that the majority of cancers (89.3%) in a popu-
lation-based PCOS cohort were detected by screening.
Compared to men with clinically diagnosed prostate can-
cer, men with screening-detected cancers were younger,
more likely to be married, less likely to be a member of a
minority group, and in better health. The cancers detected
by screening were more likely to be clinically localized
and less likely to be poorly differentiated. Among men
with clinically localized prostate cancers, those with
screening-detected cancers were significantly more likely
to undergo aggressive treatment, even after adjusting for
demographics, comorbidity, and tumor characteristics
Our finding that a high proportion of prostate cancers
diagnosed in 1994 and 1995 were detected by screening is
consistent with the temporal correlation between the
increased use of PSA testing and the increased incidence of
prostate cancer in the USA beginning during the early
1990s [4,5]. Although prostate cancer incidence rates
decreased for several years in the mid 1990s, more recent
data show that incidence rates are again increasing
[5,19,20] and survey results from the Centers for Disease
Control's Behavioural Risk Factor Surveillance System
(BRFSS) show that a high proportion of American men
continue to undergo PSA testing [20]. These data suggest
that our findings are still relevant for prostate cancers
being diagnosed in the USA. We also found that men with
screening detected cancers were more likely to have early
stage cancers, again mirroring the epidemiologic data
showing an increased incidence of early stage cancers and
a decreased incidence of advanced stage cancers [4,5]. The
majority of screening-detected tumors were moderately to
poorly differentiated; however, a significantly higher pro-
portion of clinically diagnosed cancers were poorly
differentiated.
Previous data, including an analysis of the PCOS cohort,
have shown African Americans to be twice as likely as
non-Hispanic whites to present with advanced stage can-
cers [4,5,21]. In the current analysis, we found a greater
prevalence of ethnic/racial minorities in the clinically
diagnosed versus screening-detected cancers. This dispar-
ity may reflect ethnic/racial differences in accessing pre-
ventive health care services, particularly arising from
socioeconomic barriers. This in turn could contribute to
2 – 4 9.6 13.6 14.9 14.4
5 – 7 53.4 69.9 64.6 66.5
8 – 10 22.3 8.3 11.4 10.3
Unknown 14.7 8.2 9.1 8.8
Tumor stage P < 0.01 P < 0.01 P < 0.01
Local 74.6 92.8 89.1 90.4
Regional 4.0 3.2 4.0 3.7
Advanced 21.4 4.0 7.0 5.9
*P value comparing asymptomatic cases with clinically diagnosed cases.
** P value comparing lower urinary tract symptoms alone cases with clinically diagnosed cases.
***P value comparing asymptomatic and lower urinary tract symptoms alone cases with clinically diagnosed cases.
Legend: LUTS = lower urinary tract symptoms, SEER = Surveillance, Epidemiology, and End Results; PSA = prostate-specific antigen
Table 3: Distribution of baseline demographic, socioeconomic, and clinical characteristics by screening status. (Continued)BMC Cancer 2005, 5:27 http://www.biomedcentral.com/1471-2407/5/27
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Table 4: Multivariate model of factors associated with undergoing aggressivea treatment for clinically localized cancer (n = 2796).
Variable Received aggressive treatment Wald F P-value
Adjusted percentages (95% CI) Odds ratio (95% CI)
Screening history 0.05
Not-screened 76 (74, 78) 1.0
Screened 70 (64, 76) 1.5 (1.1 – 2.3)
SEER registry < 0.01
Los Angeles 71 (67, 75) 1.0
Atlanta 89 (85, 93) 4.8 (2.7 – 8.5)
Connecticut 77 (73, 81) 1.5 (1.1 – 2.2)
New Mexico 72 (66, 78) 1.1 (0.7 – 1.7)
Seattle 73 (67, 79) 1.2 (0.8 – 1.8)
Utah 77 (73, 81) 1.5 (1.0 – 2.3)
Ethnicity < 0.01
Non-Hispanic white 76 (74, 78) 1.0
Non-Hispanic black 69 (63, 75) 0.6 (0.4 – 0.9)
Hispanic 79 (75, 83) 1.2 (0.8 – 1.9)
Age < 0.01
< 49 95 (92, 100) 1.0
50–64 89 (87, 91) 0.4 (0.2 – 1.2)
65–74 79 (77, 81) 0.2 (0.1 – 0.5)
75+ 41 (35, 47) 0.03 (0.01 – 0.08)
Current marital status < 0.01
Married 77 (75, 79) 1.0
Unmarried 71 (67, 75) 0.6 (0.5 – 0.8)
Education 0.95
< High school degree 76 (72, 80) 1.0
High school/college 76 (74, 78) 1.0 (0.7 – 1.3)
College degree 76 (72, 80) 0.9 (0.7 – 1.4)
Insurance 0.25
Private 76 (74, 78) 1.0
Medicare/Public 74 (68, 80) 0.9 (0.6 – 1.4)
Unknown 81 (75, 87) 1.6 (0.9 – 2.8)
Income (annual) 0.98
< $20,000 76 (72, 80) 1.0
$20 – 40,000 76 (72, 80) 1.0 (0.7 – 1.4)
$40,000 + 76 (72, 80) 1.0 (0.7 – 1.5)
Comorbid conditions 0.01
None 78 (74, 82) 1.0
1 77 (73, 81) 0.9 (0.7 – 1.2)
2 77 (73, 81) 0.9 (0.6 – 1.3)
3+ 68 (62, 74) 0.5 (0.3 – 0.7)
Health status < 0.01
Excellent 80 (76, 84) 1.0
Good 77 (75, 79) 0.8 (0.5 – 1.2)
Fair or poor 67 (61, 73) 0.4 (0.3 – 0.7)
PSA (ng/ml) < 0.01
<4 69 (63, 75) 1.0
≥  4 77 (75, 79) 1.7 (1.1 – 2.6)
Unknown 68 (60, 76) 0.9 (0.5 – 1.9)
Gleason score < 0.01
2 – 4 68 (62, 74) 1.0
5 – 7 78 (76, 80) 2.0 (1.4 – 2.8)
8 – 10 71 (65, 77) 1.2 (0.7 – 2.0)
Unknown 80 (74, 86) 2.3 (1.3 – 4.2)
aAggressive treatment was defined as radical prostatectomy or radiation therapy.
Legend: SEER = Surveillance, Epidemiology, and End Results; PSA = prostate-specific antigenBMC Cancer 2005, 5:27 http://www.biomedcentral.com/1471-2407/5/27
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disparities in cancer stage at diagnosis [22-24]. However,
African Americans also have been reported to demon-
strate more skeptical attitudes towards screening [25] and
the stage disparity could be due to racial differences in
tumor aggressiveness [26].
Men with screening-detected clinically localized cancers
were more likely to undergo aggressive treatment with
radical prostatectomy or radiation therapy than men with
clinically diagnosed cancers. The odds ratio for receiving
aggressive treatment was statistically significant at 1.5, but
the adjusted absolute difference between screening-
detected and clinically diagnosed cases was only 6 per-
centage points. This modest association between screen-
ing status and treatment selection suggests that clinical
practice may be only partly consistent with the American
College of Physicians' view that "aggressive treatment is
necessary to realize any benefit from the discovery of a
tumor [27]." Our findings may reflect the scientific uncer-
tainty about whether and how to treat screening-detected
prostate cancers [28].
Our study has some potential limitations. We classified
men presenting with symptoms of advanced cancer as
being clinically diagnosed. We do not know that these
symptoms actually prompted diagnostic PSA testing.
However, the tumor registry medical record abstractors
are trained to identify the events leading to a cancer diag-
nosis; they would attempt to record only symptoms con-
sistent with cancer. Classifying PSA as a screening test is
also difficult given the high prevalence of lower urinary
tract symptoms in older men [15]. Few members of our
study cohort were truly asymptomatic because nearly two-
thirds reported lower urinary tract symptoms. However,
our classifications for clinical diagnosis and screening
detection were internally valid because men diagnosed
with symptoms of advanced cancer were significantly
more likely to present with advanced stage and more
aggressive cancers than the combined group of men who
were either asymptomatic or had only lower urinary tract
symptoms. Additionally, when we compared demo-
graphic and socioeconomic characteristics across groups,
we generally found that the men with lower urinary tract
symptoms alone most closely resembled the asympto-
matic men.
Selection bias may have occurred because 44% of the sam-
pled patients did not complete the 6-month survey.
Responders were younger than non-responders, more
likely to be non-Hispanic white, had higher socioeco-
nomic status, had earlier stage disease, and were more
likely to receive radical prostatectomy. Results may be less
generalizable to older men, those with lower socioeco-
nomic status, or members of racial/ethnic groups other
than non-Hispanic white. However, these were also the
groups who were less likely to have screening-detected
cancers. We do not believe that including these non-
responders would have altered our findings on the differ-
ences between screening-detected and clinically diag-
nosed cancers. However, based on their demographics,
socioeconomic status, and advanced disease stage, the
non-responders were not likely to have a high proportion
of screening-detected cancers and thus we may have over-
estimated the proportion of screening-detected cancers.
Another potential limitation arose from asking subjects to
recall their baseline symptoms 6 months after diagnosis.
Recall errors could lead us to misclassify screening status.
However, Legler and colleagues prospectively studied a
subset of PCOS subjects and found high concordance for
symptom recall at 6-months after diagnosis compared
with reports at the time of diagnosis [29]. Finally, we may
have had incomplete symptom data, particularly for ques-
tions appearing only in the medical record abstract. The
abstracts would report a symptom if it appeared in the
medical records; the absence of a symptom could be due
to either the patient being asymptomatic or the physi-
cian's failure to ask about or record the symptom. We per-
formed a sensitivity analysis by using only subject
reported symptoms from the survey, then only symptoms
reported on the medical record abstract, and then ulti-
mately using a combination of both sources. The results
for all analyses were essentially the same.
Conclusion
The great majority of prostate cancers diagnosed in our
study cohort were detected by screening. Appropriately,
younger and healthier men were more likely to be diag-
nosed by screening. Minority status and lower socioeco-
nomic status appeared to be screening barriers. Screening
detected earlier stage and less histologically aggressive
prostate cancers. After adjusting for baseline demo-
graphic, socioeconomic, clinical, and tumor factors, men
with a screening-detected clinically localized cancer were
slightly more likely to receive aggressive treatment, either
radical prostatectomy or radiation therapy, than men with
clinically diagnosed cancers.
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